Drug That Treats Both Obesity and Diabetes
A drug that can help people shed excess weight and at the same time treat type II diabetes may soon be a reality.
Obesity and diabetes are among the biggest threats in the modern society as more and more people continue to fall victims to the conditions. Many medics and scientists state that if nothing is done now, the future generations may be at a high risk.
According to the Centres for Disease Control and Prevention (CDC), about 78.6 million Americans or 34.9% of the population are suffering from obesity. The report indicates that since the 1980s, obesity has doubled in children and tripled in adults. The George Washington University's National Centre for Health and Wellness reported that treating and managing type II diabetes hit a record high last year and cost the economy $305.1 billion.
The American Diabetes Association (ADA) reports that the disease is ranked 7th for causing death. The CDC reports that 1 in 10 adults have diabetes and type II accounts for 90-95 percent of the cases.
A breakthrough seems to have been found as a Danish Pharmaceutical Company claims that it has developed a drug that is effective on both obesity and type II diabetes, and does not cause any side effects.
During the annual conference for the Endocrine Society that was held in Boston, Novo Nordisk presented a report showing the effectiveness of Liraglutide in combating obesity and treating prediabetes and type II diabetes.
Liraglutide is not yet approved in the US but is currently marketed as Saxenda. Reports indicate that the firm made over $3.5 billion in revenue in 2015.
During an experiment that took three years to conclude, researchers from Nova Nordisk tested the drug on obese mice that were also affected by diabetes. At the end of the experiment, it was discovered that in addition to eradicating the excess body fat, the insulin production was moderated.
The report presentation during the annual conference was aimed at seeking support from doctors and healthcare givers and convincing the Food and Drug Administration (FDA) to approve Liraglutide as a treatment for obesity and type II diabetes.
It is now up to the FDA to undertake the necessary steps to ascertain the validity of the claims though it is already being used outside the region. Many people hope for the feedback to be positive, and if the drug gets the green light, we may soon be seeing a decline in cases of obesity and diabetes.